- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02330848
Walnut Ingestion in Adults at Risk for Diabetes: Effects on Body Composition, Diet Quality, and Cardiac Risk Measures (Walnut3)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Specific Aims
- To determine the effects of a walnut-included diet (with or without caloric intake adjustment) versus walnut-excluded diet on diet quality in adults at risk for diabetes. Specifically, to show that a walnut-included diet, as compared to a walnut-excluded diet will improve overall diet quality as measured by the Alternative Healthy Eating Index in adults at risk for diabetes.
- To determine the effects of a walnut-included diet (with or without caloric intake adjustment) versus walnut-excluded diet on body composition in adults at risk for diabetes. Specifically, to show that a walnut-included diet, as compared to a walnut-excluded diet for 6 months will improve body fat percentage in adults at risk for diabetes.
- To assess the effects of a walnut-included diet (with or without caloric intake adjustment) for a 6-month period on endothelial function, lipid panel levels, fasting glucose level, fasting insulin level and anthropometric measures in adults at risk for diabetes. Specifically, to show clinically meaningful improvement in endothelial function, lipid panel, fasting blood glucose, hemoglobin A1c (HbA1c), anthropometric measures and endothelial function with inclusion of walnuts in the diet in adults at risk for diabetes.
Hypotheses
- A walnut-included diet with or without dietary counseling to adjust caloric intake will improve diet quality in adults at risk for diabetes.
- A walnut-included diet for 6 months with or without dietary counseling to adjust caloric intake will improve body composition in adults at risk for diabetes.
- A walnut-included diet with or without dietary counseling to adjust caloric intake will improve lipid panel, fasting blood glucose, hemoglobin A1c, endothelial function and anthropometric measures in adults at risk for diabetes.
- Controlling calorie intake to keep it constant with the addition of walnuts to the diet will enhance the beneficial effects of walnut ingestion on diet quality, body composition, and vascular function.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Connecticut
-
Derby, Connecticut, United States, 06418
- Yale-Griffin Prevention Research Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male and female age 25-75 years;
- Non-smoker;
High risk for diabetes, defined as meeting at least one of the criteria listed below:
a. Overweight with increased waist circumference; b.Pre-diabetes: fasting blood glucose >100mg/dL and <126mg/dL or HbA1C 5.7-6.4 % c. Metabolic syndrome, i.e. meet three out of five of the following criteria: i.Blood pressure >130/85 mmHg or currently taking antihypertensive medication; ii. Fasting plasma glucose (FPG) >100 mg/dL (6.1 mmol/L); iii.Serum triglycerides level (TG)>150 mg/dL (1.69 mmol/L); iv. High-density lipoprotein (HDL) cholesterol < 40 mg/dL (1.04 mmol/L) in men, and < 50 mg/dL (1.29 mmol/L) in women; v. Overweight (BMI ≥25kg/m²) with waist circumference of more than 40 inches (102 cm) for men and more than 35 inches (88 cm) for women.
Exclusion Criteria
- Allergy to walnuts or any other nuts;
- Anticipated inability to complete study protocol for any reason;
- Current eating disorder;
- Restricted diets by choice (i.e., vegetarian, vegan);
- Receiving pharmacotherapy for obesity, including appetite suppressant
- Unstable use of lipid-lowering, antihypertensive medications or aspirin (i.e. dose has changed in the three months prior to enrollment) or unwilling to refrain from taking medication for 12 hours prior to endothelial function scanning;
- Regular use of high doses of vitamin E (>400IU/day) or vitamin C (>500mg/day); fish oil, flaxseed oil, omega-3 fatty acid and fiber supplement unless welling to discontinue supplementation for the study duration.
- Use of insulin, glucose-sensitizing medication, vasoactive medication (including glucocorticoids, antineoplastic agents, psychoactive agents, or bronchodilators);
- Diagnosed diabetes;
- Diagnosed sleep apnea;
- Established cardiovascular disease (including symptomatic coronary artery disease (CAD), myocardial infarction, peripheral vascular disease, congestive heart failure, carotid stenosis);
- Coagulopathy, known bleeding diathesis, or history of clinically significant hemorrhage; current use of warfarin;
- Regular exercise defined as participation in moderate-intensity exercise > 150 minutes/week.
- Substance abuse (chronic alcoholism, other chemical dependency)
- Any unstable medical condition that would limit the ability of a subject to participate fully in the trial (e.g., cancer, AIDS, tuberculosis, psychotic disorder)
- Women who get Depo-Provera shots
- Women who are pregnant or lactating
- Women who are currently on hormone replacement therapy
- Substance abuse (chronic alcoholism, other chemical dependency)
- Any unstable medical condition that would limit the ability of a subject to participate fully in the trial (e.g., cancer, AIDS, tuberculosis, psychotic disorder)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Walnut Ad libitum diet
Participants will be provided 392 grams of walnuts per week (56g or 2 oz/day) to include in their diet.
Their calorie intake will not be subsequently monitored or regulated, and thus will be allowed to float ad libitum.
|
Participants will be provided 392 grams of walnuts per week (56g or 2 oz/day) to include in their diet.
Their calorie intake will not be subsequently monitored or regulated, and thus will be allowed to float ad libitum
|
|
Active Comparator: Walnut Calorie Controlled
The intervention group participants will meet with a registered dietitian and receive instructions and recipes for inclusion of 392 grams of walnuts per week (56g or 2 oz/day) in their meal plan.
Participants will receive on-going instruction to preserve an isocaloric condition after the addition of walnuts.
The study dietitian will customize dietary adjustments to make room for walnuts in the diet, while accommodating the priorities of each study participant.
The general approach will emphasize general reduction in portion sizes; participants will also receive advice, based on baseline dietary intake analysis, of food eliminations that they might want to consider.
|
The intervention group participants will meet with a registered dietitian and receive instructions and recipes for inclusion of 392 grams of walnuts per week (56g or 2 oz/day) in their meal plan for 6 months.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Diet Quality assessed using the Alternative Healthy Eating Index (AHEI)
Time Frame: 6 months
|
To help the study team track any variation in dietary pattern over the course of the study, all participants will be asked at five different time points to provide information on the foods and beverages that they consumed.
A 3-day food diary record will be collected along with a one 24-hour recall using a web-based Automated Self-Administered 24-Hour Recall (ASA24) (available from the National Cancer Institute at http://riskfactor.cancer.gov/tools/instruments/asa24/)
which will guide them through the process of completing the recall data.
Diet quality will be assessed using the Alternative Healthy Eating Index (AHEI).
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Body Composition measured using bioelectrical impedance analysis and SC-240 Body Composition Analyzer
Time Frame: 6 months
|
Body composition will be measured using bioelectrical impedance analysis, which uses the resistance of electrical flow through the body to estimate body fat.
The Tanita SC-240 Body Composition Analyzer will be used to measure body composition.
The SC-240 Body Composition Analyzer measures weight and calculates body fat% and total body water% in addition to BMI.
|
6 months
|
|
Endothelial Function (EF) Assessment using the brachial artery reactivity studies (BARS) methodology
Time Frame: 6 months
|
The brachial artery reactivity studies (BARS) methodology employed is as described in the published, "Guidelines for Ultrasound Assessment of Endothelial-dependent Flow-mediated Vasodilation of the Brachial Artery."
The measure of interest is flow-mediated dilatation of the brachial artery.
|
6 months
|
|
Anthropometric Measures
Time Frame: 6 months
|
Body weight will be measured using a calibrated digital scale while height will be measured by using a calibrated stadiometer.
Body mass index (BMI) will be calculated as weight (kg) divided by height in meters (m) squared.
Waist circumference will be measured using guidelines of the National Obesity Expert Panel Report.
|
6 months
|
|
Lipid Profile
Time Frame: 6 months
|
The lipid profile is determined as follows: Total cholesterol (Tchol), triglycerides (TRIG), and high-density lipoprotein (HDL) are obtained by direct measurements.
Very-low-density lipoprotein (VLDL) and low-density-lipoprotein (LDL) are obtained by calculation: VLDL = TRIG/5; and LDL = Tchol - (VLDL + HDL).
HDL:Tchol ratio will be used to evaluate the impact of walnuts on the lipid profile.
|
6 months
|
|
Fasting Blood Glucose
Time Frame: 6 months
|
6 months
|
|
|
HbA1C
Time Frame: 6 months
|
6 months
|
|
|
Physical Activity assessed by the International Physical Activity Questionnaire (IPAQ)
Time Frame: 6 months
|
Physical activity will be assessed by the International Physical Activity Questionnaire (IPAQ).
The IPAQ is a valid and reliable tool to assess physical activity in adults.
It is a more comprehensive tool containing information on weekly activities in household and yard-work activities, occupational activity, transport, leisure time physical activity and sedentary behavior.
|
6 months
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Njike VY, Costales VC, Petraro P, Annam R, Yarandi N, Katz DL. The Resulting Variation in Nutrient Intake With the Inclusion of Walnuts in the Diets of Adults at Risk for Type 2 Diabetes: A Randomized, Controlled, Crossover Trial. Am J Health Promot. 2019 Mar;33(3):430-438. doi: 10.1177/0890117118791120. Epub 2018 Aug 1.
- Njike VY, Yarandi N, Petraro P, Ayettey RG, Treu JA, Katz DL. Inclusion of walnut in the diets of adults at risk for type 2 diabetes and their dietary pattern changes: a randomized, controlled, cross-over trial. BMJ Open Diabetes Res Care. 2016 Oct 19;4(1):e000293. doi: 10.1136/bmjdrc-2016-000293. eCollection 2016.
- Njike VY, Ayettey R, Petraro P, Treu JA, Katz DL. Walnut ingestion in adults at risk for diabetes: effects on body composition, diet quality, and cardiac risk measures. BMJ Open Diabetes Res Care. 2015 Oct 19;3(1):e000115. doi: 10.1136/bmjdrc-2015-000115. eCollection 2015.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2011-16
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
University of Colorado, DenverMassachusetts General Hospital; Ann & Robert H Lurie Children's Hospital of... and other collaboratorsRecruitingDiabetes Mellitus | Diabetes | Type 2 Diabetes | Diabetes Mellitus Type 2 | Diabetes Mellitus, Type I | Diabetes Mellitus Type II | Diabetes Mellitus, Insulin-Dependent | Diabetes, Autoimmune | Type 1 Diabetes (T1D) | Diabetes Type 2 on Insulin | Diabetes, Type IIUnited States
-
Guang NingRecruitingType 2 Diabetes Mellitus | Type1 Diabetes Mellitus | Monogenetic Diabetes | Pancreatogenic Diabetes | Drug-Induced Diabetes Mellitus | Other Forms of Diabetes MellitusChina
-
University of North Carolina, Chapel HillAmerican Diabetes AssociationNot yet recruitingType 2 Diabetes Mellitus (T2DM) | Diabetes (DM) | Insulin Dependent Diabetes | Type 1 Diabetes (T1D) | Diabetes Education | Diabetes Care | Diabetes (Insulin-requiring, Type 1 or Type 2)United States
-
University of Trás-os-Montes and Alto DouroCompletedType 2 Diabetes Mellitus | Diabetes-Related ComplicationsPortugal
-
University of North Carolina, Chapel HillAmerican Heart AssociationRecruitingType 2 Diabetes | Nutrition | Diabetes Type 2 | T2DM (Type 2 Diabetes Mellitus) | Diabetes Mellitis | T2DM | Diabetes EducationUnited States
-
Northern Care Alliance NHS Foundation TrustBrighter ABCompletedDiabetes type1 | Diabetes type2United Kingdom
-
VeraLight, Inc.InLight SolutionsUnknownGestational Diabetes | Insulin Dependent Diabetes | Non Insulin Dependent DiabetesUnited States
-
COUR Pharmaceutical Development Company, Inc.RecruitingType 1 Diabetes | Type 1 Diabetes Mellitus | T1DM | T1D | Type 1 Diabetes in Adolescence | Type 1 Diabetes in Children | Type 1 Diabetes Patients | Type 1 Diabetes Mellitis | T1DM - Type 1 Diabetes Mellitus | Type 1 Diabetes (Juvenile Onset)United States
-
Garvan Institute of Medical ResearchWeizmann Institute of ScienceCompletedType 2 Diabetes Mellitus | Pre DiabetesAustralia
Clinical Trials on Walnut Ad libitum diet
-
National Center for Complementary and Integrative...Completed
-
National Institute of Diabetes and Digestive and...CompletedHealthy VolunteersUnited States
-
Mario Negri Institute for Pharmacological ResearchIstituto Superiore di SanitàCompletedObesity | Type 2 DiabetesItaly
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
Clinical Nutrition Research Centre, SingaporeCompleted
-
Myles WolfNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National...CompletedKidney DiseaseUnited States
-
University of TorontoAlliance for Potato Research and EducationRecruitingObesity | Diabetes | Appetite Regulation | Glycemic Control | Satiety ResponseCanada
-
Pennington Biomedical Research CenterMartin, Corby, K., M.D.CompletedFood Supply | Nutrition Sciences | Climate | Waste ManagementUnited States
-
Clinical Nutrition Research Centre, SingaporeCompleted
-
PepsiCo Global R&DCompletedDietary Intake | Hydration StatusSaudi Arabia